The latest price target for Eloxx Pharmaceuticals (OTCEM:ELOX) was reported by Oppenheimer on July 11, 2023. The analyst firm set a price target for $55.00 expecting ELOX to fall to within 12 months (a possible NaN% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Eloxx Pharmaceuticals (OTCEM:ELOX) was provided by Oppenheimer, and Eloxx Pharmaceuticals maintained their outperform rating.

There is no last upgrade for Eloxx Pharmaceuticals

There is no last downgrade for Eloxx Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eloxx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eloxx Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

While ratings are subjective and will change, the latest Eloxx Pharmaceuticals (ELOX) rating was a maintained with a price target of $50.00 to $55.00. The current price Eloxx Pharmaceuticals (ELOX) is trading at is $undefined, which is out of the analyst’s predicted range.